Induction of lung progenitor cells from human iPS cells and formation of alveolar organoids.
We confirmed the induction of lung progenitor cells from human iPS cells using "PG-004," and further verified the formation of alveolar organoids from those cells.
In the process of inducing differentiation of lung progenitor cells from human iPS cells, Noggin was used in the anterior foregut induction step. As an alternative to Noggin, "PG-004" was used, and the differentiation induction efficiency of anterior foregut cells and subsequently induced ventral anterior foregut cells and lung progenitor cells was compared. After maintaining and proliferating human iPS cells (HILC01 strain) in commercially available medium (mTeSR Plus-cGMP) in an undifferentiated state, a stepwise differentiation induction was performed using the collected undifferentiated iPS cells. As a result, "PG-004" showed a concentration-dependent increase in the induction efficiency of each cell type, and particularly, results equivalent to Noggin were obtained in the induction efficiency of ventral anterior foregut and lung progenitor cells. [Summary] ■ Stepwise differentiation induction of endodermal cells, anterior foregut cells, ventral anterior foregut cells, and lung progenitor cells. ■ Formation of alveolar organoids was also confirmed using lung progenitor cells created through the differentiation induction process with "PG-004." *For more detailed test results, please download the materials from the link below.
Inquire About This Product
basic information
If you would like to check more detailed test results, please download the materials from below.
Price range
Delivery Time
Applications/Examples of results
If you would like to check more detailed test results, please download the materials from below.
catalog(1)
Download All CatalogsCompany information
PepTigrowth Co., Ltd. is advancing the development of peptides known as "growth factor alternative peptides," which possess similar activity to conventional growth factors and cytokines, utilizing the unique technology held by its shareholder, PeptideRx. We are also capable of manufacturing at GMP-grade, intended for use in clinical trials for regenerative medicine and cell therapy. We will contribute to solving the challenges faced by the pharmaceutical industry and promoting the dissemination of cell therapy and regenerative medicine.